Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Protocol ID
IntReALL HR 2010
Disease (Sub Disease)
Leukaemia (ALL)
Diagnosis Stage
Relapse/ refractory
Location
NSW, VIC, SA, NZ
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Charite University, Berlin, Germany
Collaborators
St. Anna Kinderkrebsforschung, CCRI (co-sponsor, Austria)
European Organisation for Research and Treatment of Cancer - EORTC
University Hospital Motol (Co-Sponsor Czech Republic)
Copenhagen University Hospital, Rigshospitalet (co-sponsor, Denmark)
Turku University Central Hospital (co-sponsor, Finland)Centre Hospitalier Universitaire de Nice
Our Lady's Chilrden's Hospital (Co-Sponsor Ireland)
Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)
Ospedale Pediatrico Bambino (co-sponsor, Italy)
Prinses Máxima Centrum (Co-Sponsor Netherlands)
Oslo University Hospital (co-sponsor, Norway)
Medical University of Wroclaw (Co-Sponsor Poland)
Instituto Português de Oncologia de Lisboa (co-sponsor, Portugal)
Karolinska University Hospital Stockholm (co-sponsor, Sweden)
Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)
University Children's Hospital Zürich (co-sponsor, Switzerland)
Central Manchester University Hospitals NHS Foundation Trust (co-sponsor, UK)
Trial Status
Open
Sites
The Children's Hospital at Westmead
John Hunter Children's Hospital
Monash Children's Hospital
Sydney Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
up to 18 years
International registry ID's
NCT03590171
Back to Registry
Study Title International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Protocol ID IntReALL HR 2010
Disease (Sub Disease) Leukaemia (ALL)
Diagnosis Stage Relapse/ refractory
Location NSW / VIC / SA / NZ
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ Charite University, Berlin, Germany
Collaborators St. Anna Kinderkrebsforschung, CCRI (co-sponsor, Austria)/ European Organisation for Research and Treatment of Cancer - EORTC/ University Hospital Motol (Co-Sponsor Czech Republic)/ Copenhagen University Hospital, Rigshospitalet (co-sponsor, Denmark)/ Turku University Central Hospital (co-sponsor, Finland)Centre Hospitalier Universitaire de Nice/ Our Lady's Chilrden's Hospital (Co-Sponsor Ireland)/ Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)/ Ospedale Pediatrico Bambino (co-sponsor, Italy)/ Prinses Máxima Centrum (Co-Sponsor Netherlands)/ Oslo University Hospital (co-sponsor, Norway)/ Medical University of Wroclaw (Co-Sponsor Poland)/ Instituto Português de Oncologia de Lisboa (co-sponsor, Portugal)/ Karolinska University Hospital Stockholm (co-sponsor, Sweden)/ Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)/ University Children's Hospital Zürich (co-sponsor, Switzerland)/ Central Manchester University Hospitals NHS Foundation Trust (co-sponsor, UK)
Links https://clinicaltrials.gov/ct2/show/NCT03590171
Trial Status Open
Trial Open Date 16/05/2019
Sites The Children's Hospital at Westmead / John Hunter Children's Hospital / Monash Children's Hospital / Sydney Children's Hospital / Women's & Children's Hospital / Christchurch Hospital / Starship Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility up to 18 years
International registry ID's NCT03590171